Human Mesenchymal Stem Cell Secretome Driven T Cell Immunomodulation Is IL-10 Dependent

Financial support was provided by the Ministry of Higher Education and Scientific Research, Iraq (S1443) and the Guy Hilton Asthma Trust.Peer reviewedPublisher PD

La evaluación de las incidencias de toxicidad ocular y hallazgos oculares causados por el compuesto quelante de hierro

Introduction: The current article mainly attempts to evaluate the incidences of ocular toxicity and ocular findings stemming from the iron-chelating compound, deferasirox in patients with beta-thalassemia receiving recurrent blood transfusions. Patients and methods: Nearly sixty cases with ß-thalassemia major participated as case subjects, while an additional sixty otherwise healthy volunteers were engaged as control subjects. All of the subjects were age and sex-matched, and all of the volunteers were included as case subjects. Results: Despite the fact that all of the cases with beta-thalassemia did not have any signs or symptoms of eye disease, abnormal visual features (dry eye (35%), retinal pigment changes and retinal epithelium degeneration (15%), and ocular abnormalities (36.2%) were observed in 67% of thalassemia patients, indicating that the disease is not contagious, given the findings. The incidence of visual anomalies in the control group was 18.2 %, which was significantly subtler in comparison to thalassemia patients (P≤0.001). A non-significant link exists between ocular defects and serum ferritin (P=0.543) or blood hemoglobin (P=0.265). A statistically significant connection between the frequency of blood transfusions and ocular abnormalities was discovered (P=0.001). Conclusion: Based on the results, thalassemia patients should go through regular ophthalmological examination to detect early anomalies in their visual system when using an iron chelator.Introducción: El presente artículo intenta principalmente evaluar las incidencias de toxicidad ocular y los hallazgos oculares derivados del compuesto quelante de hierro deferasirox en pacientes con beta-talasemia que reciben transfusiones de sangre recurrentes. Pacientes y métodos: Casi sesenta casos con ß-talasemia mayor participaron como sujetos de casos, mientras que otros sesenta voluntarios sanos participaron como sujetos de control. Todos los sujetos tenían la misma edad y sexo, y todos los voluntarios se incluyeron como sujetos de casos. Resultados: Apesar de que todos los casos con beta-talasemia no tenían ningún signo o síntoma de enfermedad ocular, características visuales anormales (ojo seco (35%), cambios en la pigmentación retiniana y degeneración del epitelio retiniano (15%) y se observaron anomalías visuales (36,2%) en el 67% de los pacientes con talasemia, lo que indica que la enfermedad no es contagiosa, dados los hallazgos. La incidencia de anomalías visuales en el grupo control fue del 18,2 %, que fue significativamente más sutil en comparación con los pacientes con talasemia (P≤0,001). Existe una relación no significativa entre los defectos oculares y la ferritina sérica (P=0,543) o la hemoglobina en sangre (P=0,265). Se descubrió una conexión estadísticamente significativa entre la frecuencia de las transfusiones de sangre y las anomalías oculares (P=0,001) Conclusión: En base a los resultados, es recomendable que los pacientes con talasemia se realicen un examen oftalmológico periódico para detectar tempranamente anomalías en su sistema visual al utilizar un quelante de hierro

Nivel de troponina sérica modulada por alopurinol en pacientes con cálculos renales

Cardiovascular diseases are aggravated by various factors, including chronic use of certain medications. There are worldwide reported cases of sudden strokes or myocardial infarction in previously non-ischemic patients while using medications for other chronic diseases, such as diabetes, gout, hypertension, and endocrine diseases. The mechanism is quite complicated, and the underlying causes were obscure. In line with this reported toxicity are patients with hyperuricemia on uric acid lowering therapy. The goal of the present investigation was to assess the cardiotoxic effect of allopurinol based on the levels of troponin that were quantified by fully automated COBAS technique in apparently healthy renal stone patients. To do so, serum samples were collected from these patients at baseline (before starting allopurinol therapy), and at the end of the course of the therapy. The troponin level was significantly elevated after allopurinol therapy compared to baseline. The study concluded that allopurinol could have a significant cardiotoxic effect in heart tissues and should be used cautiously in patients with pre-existing ischemic cardiac diseases.Las enfermedades cardiovasculares se ven agravadas por varios factores, incluido el uso crónico de ciertos medicamentos. Se han reportado casos en todo el mundo de accidentes cerebrovasculares repentinos o infarto de miocardio en pacientes previamente no isquémicos mientras usaban medicamentos para otras enfermedades crónicas, como diabetes, gota, hipertensión y enfermedades endocrinas. El mecanismo es bastante complicado y las causas subyacentes son oscuras. En consonancia con esta toxicidad reportada están los pacientes con hiperuricemia con tratamiento para reducir el ácido úrico. El objetivo de la presente investigación fue evaluar el efecto cardiotóxico del alopurinol en función de los niveles de troponina, cuantificados mediante la técnica COBAS totalmente automatizada en pacientes con cálculos renales aparentemente sanos. Para ello, se recolectaron muestras de suero de estos pacientes al inicio (antes de comenzar la terapia con alopurinol) y al final del curso de la terapia. El nivel de troponina incrementó significativamente en los pacientes que recibieron tratamiento con alopurinol   en comparación con el valor inicial. El estudio concluyó que el alopurinol podría tener un efecto cardiotóxico significativo en los tejidos cardíacos y debería usarse con precaución en pacientes con enfermedades cardíacas isquémicas preexistentes

Silent hyperlipidaemia modulated vascular endothelial markers

The aetiology of ischemic heart diseases is mainly based on atherosclerosis of coronary artery. Inflammation and oxidative reactions are initiating and aggravating the illness resulting in pathological remodelling of vasculaturze at site of injury. Endothelium lining of blood vessels participated in the reaction biochemically through releasing some proteins into circulatory system which further complicate the condition. The aim of this study was to determine early diagnosed hyperlipidaemia-associated changes of the plasma level of some of these endothelial biomolecules. Compared to healthy control, hyperlipidaemic patients have significantly increased arginase, metalloendopeptidase, peroxidase, myeloperoxidase, and peroxynitrite with concomitant reduction in arylesterase and nitric oxide. The present study concluded that hyperlipidaemia play a great role in modulation of certain plasma protein markers which might be directly related to patient pathological condition or could be used as a tool for diagnosis or patient follow up indicating the stage of vasculature remodelling, healing, inflammation or resolution